Emcure Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Satish Mehta
Chief executive officer
₹229.6m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 43.8yrs |
| CEO ownership | 44.7% |
| Management average tenure | 3.5yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹6b |
| Jun 30 2024 | n/a | n/a | ₹5b |
| Mar 31 2024 | ₹230m | ₹230m | ₹5b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | n/a | n/a | ₹5b |
| Mar 31 2022 | ₹235m | ₹162m | ₹7b |
Compensation vs Market: Satish's total compensation ($USD2.67M) is above average for companies of similar size in the Indian market ($USD578.33K).
Compensation vs Earnings: Satish's compensation has been consistent with company performance over the past year.
CEO
Satish Mehta (73 yo)
43.8yrs
Tenure
₹229,590,000
Compensation
Mr. Satish Ramanlal Mehta serves as the Chief Executive Officer and Managing Director at Emcure Pharmaceuticals Ltd and has been its Executive Director since April 16, 1981. Mr. Mehta has a wealth of exper...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | no data | ₹229.59m | 44.72% ₹ 124.1b | |
| Chief Financial Officer | 3.8yrs | ₹17.46m | no data | |
| President of Operations & Whole-Time Director | no data | ₹33.53m | 7.15% ₹ 19.8b | |
| Chief Scientific Officer & Whole-Time Director | no data | ₹57.70m | 0.16% ₹ 433.2m | |
| Executive Director of Projects & Whole-Time Director | no data | ₹34.45m | 13.3% ₹ 36.9b | |
| Executive Director of India Business & Whole-Time Director | no data | ₹45.96m | 2.68% ₹ 7.4b | |
| Company Secretary & Compliance Officer | 1.6yrs | no data | no data | |
| Director of Corporate Communications & Public Relations | 3.5yrs | no data | no data | |
| President of Corporate Development | no data | ₹32.56m | 0.34% ₹ 944.9m | |
| President of HR | no data | no data | no data | |
| President of Emerging Markets | no data | ₹30.92m | 9.62% ₹ 26.7b | |
| President of Technical Operations | no data | ₹21.42m | no data |
3.5yrs
Average Tenure
52.5yo
Average Age
Experienced Management: 544210's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Executive Director | 43.8yrs | ₹229.59m | 44.72% ₹ 124.1b | |
| President of Operations & Whole-Time Director | 2.5yrs | ₹33.53m | 7.15% ₹ 19.8b | |
| Chief Scientific Officer & Whole-Time Director | 23.5yrs | ₹57.70m | 0.16% ₹ 433.2m | |
| Executive Director of Projects & Whole-Time Director | 11.6yrs | ₹34.45m | 13.3% ₹ 36.9b | |
| Executive Director of India Business & Whole-Time Director | 10.5yrs | ₹45.96m | 2.68% ₹ 7.4b | |
| Independent Director | 4.5yrs | ₹3.24m | no data | |
| Independent Chairman | 27.8yrs | ₹10.60m | 0.10% ₹ 282.5m | |
| Independent Director | 3.8yrs | ₹5.32m | no data | |
| Independent Director | 3.8yrs | ₹1.78m | no data | |
| Independent Director | 3.8yrs | ₹2.26m | no data |
7.5yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 544210's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 19:25 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Emcure Pharmaceuticals Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alok Dalal | Jefferies LLC |
| Bansi Desai | J.P. Morgan |
| Sanjeev Prasad | Kotak Securities (Institutional Equities) |